These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7178231)

  • 21. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders.
    Poelinger W; Haber H
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():47-50. PubMed ID: 2644340
    [No Abstract]   [Full Text] [Related]  

  • 22. [Saliva level of free-3-methoxy-4-hydroxyphenylglycol in patients with anxiety disorders].
    Yamada S; Yajima J; Tsuda A; Yamauchi K; Maeda H; Tanaka M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Apr; 19(2):67-71. PubMed ID: 10464777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of depression in outpatients: a controlled comparison of the onset of action of amoxapine and maprotiline.
    Fabre LF
    J Clin Psychiatry; 1985 Dec; 46(12):521-4. PubMed ID: 3905772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter evaluation of maprotiline hydrochloride for treatment of depression.
    Clin Ther; 1984; 6(2):155-62. PubMed ID: 6367987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary MHPG and clinical response to amitriptyline in depressed patients.
    Spiker DG; Edwards D; Hanin I; Neil JF; Kupfer DJ
    Am J Psychiatry; 1980 Oct; 137(10):1183-7. PubMed ID: 7416262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toward a biochemical classification of depressive disorders IV: Pretreatment urinary MHPG levels as predictors of antidepressant response to imipramine.
    Schatzberg AF; Orsulak PJ; Rosenbaum AH; Maruta T; Kruger ER; Cole JO; Schildkraut JJ
    Commun Psychopharmacol; 1980; 4(5):441-5. PubMed ID: 7333096
    [No Abstract]   [Full Text] [Related]  

  • 27. Possible pathophysiological mechanisms in subtypes of unipolar depressive disorders based on differences in urinary MHPG levels [proceedings].
    Schildkraut JJ; Orsulak PJ; Schatzberg AF; Cole JO; Rosenbaum AH
    Psychopharmacol Bull; 1981 Jan; 17(1):90-91. PubMed ID: 7232668
    [No Abstract]   [Full Text] [Related]  

  • 28. 3-Methoxy-4-hydroxyphenylglycol and primary depression: clinical and pharmacological considerations.
    Sacchetti E; Allaria E; Negri F; Biondi PA; Smeraldi E; Cazzullo CL
    Biol Psychiatry; 1979 Jun; 14(3):473-84. PubMed ID: 476232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of maprotiline on target symptoms of depressive states].
    Faltus F
    Act Nerv Super (Praha); 1982 May; 24(2):99-100. PubMed ID: 7102230
    [No Abstract]   [Full Text] [Related]  

  • 30. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study].
    Raucoules D; Levy C; Azorin JM; Bruno M; Valli M
    Encephale; 1992; 18(6):611-6. PubMed ID: 1285270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
    Classen W
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():41-3. PubMed ID: 2587675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with maprotiline.
    Kabes J; Dostal T; Roth Z
    Act Nerv Super (Praha); 1982 May; 24(2):93-8. PubMed ID: 7048837
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine.
    Sharma RP; Janicak PG; Javaid JI; Pandey GN; Gierl B; Davis JM
    Am J Psychiatry; 1990 Oct; 147(10):1318-21. PubMed ID: 2169208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noradrenergic output and clinical response in depressed women during amitriptyline therapy.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Comincioli V; Zerbi F; Fenoglio L; Savoldi F
    Pharmacopsychiatry; 1989 Jul; 22(4):144-51. PubMed ID: 2762377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with maprotilin and maprotilin/clomipramine infusions in resistant depression.
    Zapletálek M; Zbytovský J; Kudrnová K
    Act Nerv Super (Praha); 1982 May; 24(2):73-6. PubMed ID: 7102227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Double blind study on maprotiline, an example of a multidimensional psychopharmacologic experiment (author's transl)].
    Bergener M; Hesse C; Hummel F; Husser J; Kern U; Neller K; Reiners I
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):63-7. PubMed ID: 347465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients.
    Timmerman L; de Beurs P; Tan BK; Leijnse-Ybema H; Sanchez C; Høpfner Petersen HE; Cohen Stuart MH
    Int Clin Psychopharmacol; 1987 Jul; 2(3):239-53. PubMed ID: 2447151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of moderate exercise on urinary MHPG in depressed patients.
    Beckmann H; Ebert MH; Post R; Goodwin FK
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Sep; 12(5):351-6. PubMed ID: 504341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study.
    Møller SE; de Beurs P; Timmerman L; Tan BK; Leijnse-Ybema HJ; Stuart MH; Petersen HE
    Psychopharmacology (Berl); 1986; 88(1):96-100. PubMed ID: 3080781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtypes of depression based on excretion of MHPG and response to nortriptyline.
    Hollister LE; Davis KL; Berger PA
    Arch Gen Psychiatry; 1980 Oct; 37(10):1107-10. PubMed ID: 6158927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.